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In this issue of Immunity, Curotto de Lafaille et al. (2008) show that adaptive T regulatory cells control airway
inflammation and that it is when they are generated that determines whether they function during acute or
chronic inflammation.The airways are constantly assaulted by
aeroantigens, yet the vast majority of indi-
viduals are tolerant and mount no immune
response. However, atopic individuals re-
spond inappropriately to these innocuous
aeroantigens and develop airway inflam-
matory disease (asthma) characterized
by remodeling and hyperresponsiveness
of the airways. That asthma is a disease
of immune dysregulation is exemplified
by the fact that affected individuals have
an elevated number of T helper 2 (Th2)
cells and Th2 cell-type cytokines in the
lung as well as elevated amounts of IgE
and lung eosinophilia (Wills-Karp, 1999).
The ability of the majority of people to re-
main unresponsive to aeroantigens has
been ascribed to the ability of regulatory
T (Treg) cells and immunomodulatory
cytokines (e.g., IL-10) to control re-
sponses (Akdis, 2006; Umetsu and
Dekruyff, 2006). Although the role of
Treg cells to control airway inflammation
has been shown in transfer models, what
role they play as disease develops re-
mains to be determined. In addition, how
aeroantigen-specific Treg cells, if they
exist, develop and function is an area of
intense investigation and discussion. The
data in Curotto de Lafaille et al. (2008)
begin to develop a framework for uncov-
ering the role of Treg cells in both acute
and chronic airway inflammation in thelung, and, by extension, other mucosal
surfaces.
In naive mice, the outcome of an en-
counter with an inhaled antigen, in the
absence of an inflammatory stimulus, is
tolerance, not activation. However, this
tolerance is not the result of a lack of a re-
sponse to the antigen, as shown by the
fact that robust CD4+ T cell proliferation
is seen in draining lymph nodes after treat-
ment (Hammad and Lambrecht, 2008).
Rather, it may be due to incomplete den-
dritic cell activation, resulting in either
aborted T cell activation and subsequent
deletion or the generation of T cells
with regulatory activity (Hammad and
Lambrecht, 2008). These tolerized mice
are then resistant to subsequent challenge
with the same antigen in the presence of
an inflammatory stimulus. In addition,
adoptive transfer of antigen-specific Treg
cells can inhibit disease development,
and depletion of CD4+CD25+ cells in-
creases disease parameters in challenged
mice (Lewkowitch et al., 2005), further
supporting an important role for Treg cells
in controlling inflammation in airways.
The mechanism by which these Treg
cells control airway inflammation is not
at all clear. Several reports have sug-
gested that Treg cells block inflammation
in an IL-10-dependent manner. For exam-
ple, either transfer of Treg cells fromImmuIL-10-deficient mice or IL-10 blockade
after transfer of Treg cells abolished inhi-
bition of airway inflammation (Kearley
et al., 2005). In contrast, Treg cells in-
duced by helminth infection are capable
of completely inhibiting allergic airway
inflammation in an IL-10-independent
manner (Wilson et al., 2005).
Several important issues remain to be
resolved concerning the role of Treg cells
in controlling airway inflammation. These
include whether the Treg cells seen in
these models are thymically derived,
what the role of Foxp3 is in their genera-
tion and function, and what role, if any, in-
flammation plays in controlling Treg cell
generation and function. By using a very
elegant and simple system, Curotto de
Lafaille et al. (2008) provide insight into
these issues. They take advantage of
mice whose T and B cell repertoires are
non-self reactive and monoclonal through
expression of a single T cell receptor
(TCR) and BCR in a Rag-deficient back-
ground (referred to as T-Bmc mice). Sim-
ilar to other TCR transgenic mice in
a Rag-deficient host, these mice lack
thymically derived, ‘‘natural,’’ Treg cells,
and thus can be used to determine the
role of adaptive Treg cells in tolerance to
aeroantigens. The other advantage of
these mice is that they can be rendered
Foxp3 deficient without causing thenity 29, July 18, 2008 ª2008 Elsevier Inc. 5
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ing a determination of Foxp3’s role in this
process. Although not a perfect system
(e.g., the role of CD8+ T cells cannot be
addressed), it is ideal for a specific exam-
ination of the role of Foxp3 in the genera-
tion and function of adaptive Treg cells.
This group had previously shown that
oral administration of ovalbumin (OVA)
drove the generation of Foxp3+ Treg cells
in the T-Bmc mice (Mucida et al., 2005). In
the current study they show that, not sur-
prisingly, generation of these Treg cells
requires Foxp3. An interesting feature of
these experiments was the finding that
in the T-Bmc mice lacking Foxp3, oral
administration of OVA did not lead to the
generation of effector T cells. These data
are somewhat surprising given the recent
report of a reciprocal relationship between
adaptive Treg and Th17 cells (Zhou et al.,
2008), and support instead the view that
distinct microenvironments in the gut are
responsible for Treg and effector T (Teff)
cell differentiation. However, another pos-
sible explanation is that in the absence of
adjuvant, DCs are not sufficiently mature
to drive effector differentiation.
An important aspect of this work is
a better understanding of not how, but
when, Treg cells exert their influence
over inflammatory responses (Figure 1).
Not surprisingly, in mice given oral OVA
prior to immunization and challenge, no
appreciable airway inflammation was
found. In these mice, the presence of6 Immunity 29, July 18, 2008 ª2008 Elsevierantigen-specific Treg cells inhibits at the
priming stage, and thus no response can
develop. However, in naive animals (lack-
ing both thymic and adaptive Treg cells),
Teff and Treg cells develop side by side
after sensitization. These Treg cells are in-
effective at suppressing inflammation, as
shown by the fact that the level of inflam-
mation is the same in the presence and
absence of Foxp3 in the mice. One reason
for this difference may be timing—Teff,
but not Treg, cells are capable of crossing
the epithelial border and enter the air-
ways. Treg cells enter the airways only
after an antigen challenge, giving the ef-
fectors a ‘‘head start’’ on developing an
inflammatory response. Where these
Treg cells are effective is in suppressing
responses after chronic exposure to anti-
gen. T-Bmc mice lacking Foxp3 develop
more severe inflammation that includes
disseminated IL-4 production, the devel-
opment of organized lymphoid follicles
(BALT) in the lung, and smooth muscle
hypertrophy. Interestingly, and in contrast
to other systems (Kearley et al., 2005),
IL-10 amounts decrease, along with cyto-
kines, in the Foxp3+ T-Bmc mice, and
remain at high amounts in the T-Bmc
mice lacking Foxp3, suggesting that
IL-10 plays little or no role in resolving
inflammation in this model. It should be
noted that the Foxp3+ Treg cells in these
mice do not suppress all aspects of in-
flammation—IL-5 production and the
resulting lung eosinophilia appear to beInc.inhibited by a Foxp3-independent mech-
anism involving IFN-g.
Taken as a whole, the data presented
propose an important role for adaptive
Treg cells in controlling inflammation and
suggest that the timing of Treg cell gener-
ation ultimately determines the outcome
of an encounter with antigen. Passive an-
tigen encounter, for example through the
airways, creates a tolerizing environment
through the generation of antigen-specific
Treg cells. These Treg cells can then sup-
press responses if a more active encoun-
ter with the same antigen occurs. If the
first encounter with an antigen is active
(via infection, for example), then acute
inflammation can occur, but Treg cells
generated during the initial response will
inhibit subsequent chronic inflammation.
In the airways, this could be from an early
respiratory viral infection.
What these data do not explain, and
what remains the major question in this
field, is what happens in individuals who
develop chronic airway diseases like
asthma? The model described above
would posit that most individuals should
be tolerized against aeroantigens through
passive interactions and should also be
protected from other antigenic challenges
through generation of adaptive immunity.
Because asthmatics develop chronic
inflammatory disease as a response to in-
nocuous aeroantigen, it would appear that
neither of these pathways is operative.
This could be due to a defect in the ability
to generate adaptive Treg cells or (as is
now becoming apparent in some autoim-
mune settings) due to the generation of
effector T cells that are resistant to sup-
pression. Other possibilities include de-
fects in other cell populations in the lung,
such as the airway epithelium, resulting
in inappropriate production of cytokines
(such as IL-25 or TSLP) that may drive
Th2 cell-type differentiation at the ex-
pense of Treg cells. Obviously more work
is needed to better understand these
problems, and the T-Bmc model is a
good place to start.
REFERENCES
Akdis, M. (2006). Curr. Opin. Immunol.18, 738–744.
Curotto de Lafaille, M.A., Kutchukhidze, N., Shen,
S., Ding, Y., Yee, H., and Lafaille, J.J. (2008).
Immunity 29, this issue, 114–126.
Hammad, H., and Lambrecht, B.N. (2008). Nat.
Rev. Immunol. 8, 193–204.Figure 1. Timing of Adaptive Treg Cell Generation Determines Outcome
Top: OVA-specific adaptive Treg cells, generated via oral administration of antigen prior to sensitization
and challenge (allergen ), can successfully inhibit inflammatory responses in the lung.
Bottom: In the absence of pre-existing allergen-specific Treg cells, sensitization and challenge (allergen +)
results in the onset of acute inflammation, as well as the generation of allergen-specific Treg cells. Al-
though these Treg cells are incapable of inhibiting acute inflammation, they can ameliorate inflammation
if antigen is given chronically.
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Since the initial description of the T helper
1 (Th1) and Th2 subsets, the study of T
helper cells has been dominated by ques-
tions about the events that lead to Th cell
differentiation and the role of cytokines
and transcription factors that prompt indi-
vidual T cells to adopt different fates.
More recently, with the characterization
of regulatory T cells (Treg) and Th17 cells,
many of these same issues have been re-
visited in slightly different contexts. More-
over, with the advent of improved ways to
assay polyfunctionality in T cells, it is be-
coming apparent that defining a T cell lin-
eage based on the production of a single
cytokine or expression of a particular tran-
scription factor has its limitations. This in
turn has led to debate about whether the
paradigm of T cell subsets is still useful
and how to characterize phenotypic plas-
ticity within T cell populations. Neglected
by many in the midst of these delibera-
tions is the original reason that CD4+ T
cells were ascribed a helper function: their
ability to provide cognate help to B cells
required for the generation of high-affinity
antibodies and memory. These interac-
tions between T and B cells provide an im-
portant checkpoint for the development
of protective antibody responses and
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te high-affinity antibodies. Two paper
08) have identified a role for interleu
tions about how this dedicated popu
peripheral B cell tolerance. However, given
the distinct compartmentalization of T and
B cells within secondary lymphoid tis-
sues, there needs to be a process that
brings relevant lymphocytes together.
Thus, antigen-stimulated B cells accumu-
late at the margins of the B cell areas
where they elicit T cell help. This carefully
choreographed event is dependent on the
ability of T cells to provide costimulation
to the B cells that leads to the seeding of
follicles with B and T cells and lymphocyte
proliferation accompanied by differentia-
tion and somatic hypermutation to give
rise to plasma cells secreting high-affinity
antibodies. The migration of Th cells to the
edge of the B cell zones and the follicular
regions and germinal centers rich in the
chemokine CXCL13 is linked to the
expression of the chemokine receptor
CXCR5 (Ansel et al., 2000).
Until relatively recently, there has been
a poor understanding of the Th cells that
are involved in this process, and one
model was that Th1 or Th2 cells provided
help to B cells through shared mecha-
nisms that include costimulatory inter-
actions through CD40-CD40L or ICOS-
ICOSL or their ability to produce specific
B cell growth factors. Consistent with
this notion was the association of their
ImmuWilson, M.S., Taylor, M.D., Balic, A., Finney,
C.A.M., Lamb, J.R., and Maizels, R.M. (2005). J.
Exp. Med. 202, 1199–1212.
Zhou, L., Lopes, J.E., Chong, M.M., Ivanov, I.I.,
Min, R., Victora, G.D., Shen, Y., Du, J., Rubtsov,
Y.P., Rudensky, A.Y., et al. (2008). Nature 453,
236–240.m 313,
s in this issue of Immunity (Nurieva
kin-21 in the development of these
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signature cytokines IFN-g and IL-4 with
class switching and particular IgG iso-
types. In contrast, the first transcriptional
profiling of CXCR5+ CD4+ T cells was
more in line with the idea that T follicular
helper (Tfh) cells were a distinct subset
(Chtanova et al., 2004). Indeed, from these
studies came the ideas that Tfh cells make
IL-10 and IL-21, which are not typically
associated with Th1 orTh2 cells, but which
provide proliferative signals to B cells.
In the last month, three manuscripts
have addressed the relationship of Tfh
cells with other T cell subsets and identify
IL-21 as a key cytokine that promotes the
development of these specialized effector
cells (Nurieva et al., 2008; Suto et al.,
2008; Vogelzang et al., 2008). IL-21 is
closely related to other potent T cell
growth factors, such as IL-2 and IL-15,
and signals through the shared common
g chain. Previous studies had shown
that B cells express the IL-21R, that
IL-21 promotes growth of mature B cells,
and that Il21r/ mice had reduced B
cell responses (Spolski and Leonard,
2008). Together, these studies were con-
gruent with the idea that Tfh cells are
a source of IL-21 that drives B cell expan-
sion within germinal centers. However,
these more recent publications have
nity 29, July 18, 2008 ª2008 Elsevier Inc. 7
